- Home
- SNGX vs GTBP Comparison
SNGX vs GTBP Comparison
Compare SNGX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- GTBP
- Stock Information
- Founded
- SNGX 1987
- GTBP 1965
- Country
- SNGX United States
- GTBP United States
- Employees
- SNGX N/A
- GTBP N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- GTBP Health Care
- Exchange
- SNGX Nasdaq
- GTBP Nasdaq
- Market Cap
- SNGX 7.4M
- GTBP 6.8M
- IPO Year
- SNGX 1987
- GTBP N/A
- Fundamental
- Price
- SNGX $2.35
- GTBP $2.39
- Analyst Decision
- SNGX
- GTBP Strong Buy
- Analyst Count
- SNGX 0
- GTBP 1
- Target Price
- SNGX N/A
- GTBP $11.00
- AVG Volume (30 Days)
- SNGX 619.7K
- GTBP 1.3M
- Earning Date
- SNGX 03-14-2025
- GTBP 11-14-2024
- Dividend Yield
- SNGX N/A
- GTBP N/A
- EPS Growth
- SNGX N/A
- GTBP N/A
- EPS
- SNGX N/A
- GTBP N/A
- Revenue
- SNGX $364,183.00
- GTBP N/A
- Revenue This Year
- SNGX N/A
- GTBP N/A
- Revenue Next Year
- SNGX $76.64
- GTBP N/A
- P/E Ratio
- SNGX N/A
- GTBP N/A
- Revenue Growth
- SNGX N/A
- GTBP N/A
- 52 Week Low
- SNGX $1.83
- GTBP $1.72
- 52 Week High
- SNGX $14.88
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- SNGX 34.04
- GTBP 42.95
- Support Level
- SNGX $2.03
- GTBP $2.32
- Resistance Level
- SNGX $3.44
- GTBP $2.63
- Average True Range (ATR)
- SNGX 0.33
- GTBP 0.27
- MACD
- SNGX -0.08
- GTBP -0.05
- Stochastic Oscillator
- SNGX 19.39
- GTBP 33.00
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.